Ask AI
Adjuvant CDK4/6i in HR Pos EBC

CE

Adjuvant CDK4/6 Inhibitors in High-Risk HR+/HER2− EBC: Managing AEs and Administration Considerations to Optimize Adherence

Pharmacists: 0.25 contact hour (0.025 CEUs)

Released: January 29, 2026

Expiration: July 28, 2026

Pretest

Progress
1 2 3
Course Completed
Please answer the questions below.
1.

A patient receiving adjuvant abemaciclib (150 mg BID) develops grade 2 diarrhea that persists for 48 hours despite consistent loperamide use beginning during the first episode of diarrhea. According to the prescribing information, what would you recommend next to manage this diarrhea?

2.

Which multidisciplinary intervention is best supported by evidence and guideline-based practice for reducing the risk of early discontinuation for oral CDK4/6 inhibitors in patients with hormone receptor (HR)–positive/HER2-negative early breast cancer (EBC)?

3.

A 30% increase in serum creatinine (SCr) is observed during cycle 1 of abemaciclib for your patient with HR-positive/HER2-negative breast cancer and no prior history of kidney disease. How would you manage this finding to avoid unnecessary treatment discontinuation?